Zoetis

ZTS Health Care Market cap $30.4B as of Sep 14, 2026 16:03 ET S&P 500

Q2 FY26 Apr 1 – Jun 30, 2026 reported Aug 6, 2026

Revenue$2.47B +0% year over year

Gross profit$1.80B 73% margin

Operating profit$0.86B 35% margin

Net profit$0.69B 28% margin

The numbers behind the diagram

All figures in billions of U.S. dollars, for Q2 FY26 (period ends Jun 30, 2026).
Item	Value	Share of revenue	Year over year
Revenue	2.47	100%	+0%
Livestock	0.73	29%
Dermatology	0.40	16%
Cattle	0.39	16%
Other revenue	0.32	13%
Pain sedation	0.22	9%
Other pharmaceuticals	0.17	7%
Animal health diagnostics	0.12	5%
Swine	0.12	5%
Cost of revenue	−0.67	27%
Gross profit	1.80	73% margin
SG&A	−0.59	24%	−1pp
Other	−0.34	14%
Operating profit	0.86	35% margin	−2pp
Tax	−0.17
Net profit	0.69	28% margin	−1pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Mar 31, 2026).
Item	Value	Share of revenue	Year over year
Revenue	2.26	100%	+3%
Livestock	0.72	32%
Dermatology	0.35	15%
Other revenue	0.35	15%
Anti infective products	0.24	11%
Pain sedation	0.20	9%
Other pharmaceuticals	0.16	7%
Swine	0.12	6%
Poultry	0.12	5%
Cost of revenue	−0.64	28%
Gross profit	1.62	72% margin	+0pp
SG&A	−0.59	26%	+0pp
Other	−0.30	13%	+0pp
Operating profit	0.74	33% margin	−2pp
Other income, net	0.02
Tax	−0.16
Net profit	0.60	27% margin	−1pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q4 FY25 (period ends Dec 31, 2025).
Item	Value	Share of revenue	Year over year
Revenue	2.41	100%	+4%
Parasiticides	0.54	22%
Vaccines	0.51	21%
Dermatology	0.43	18%
Anti infective products	0.28	12%
Other revenue	0.21	9%
Other pharmaceuticals	0.19	8%
Swine	0.13	5%
Poultry	0.12	5%
Cost of revenue	−0.72	30%
Gross profit	1.69	70% margin	+1pp
SG&A	−0.61	25%	−2pp
Other	−0.30	13%	+0pp
Operating profit	0.79	33% margin	+2pp
Tax	−0.15
Net profit	0.63	26% margin	+1pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	2.40	100%	+1%
Parasiticides	0.56	23%
Vaccines	0.50	21%
Dermatology	0.47	20%
Other revenue	0.27	11%
Pain sedation	0.20	8%
Other pharmaceuticals	0.18	7%
Swine	0.11	5%
Animal health diagnostics	0.11	5%
Cost of revenue	−0.68	28%
Gross profit	1.72	72% margin	+1pp
SG&A	−0.58	24%	+0pp
Other	−0.26	11%	+0pp
Operating profit	0.87	36% margin	+0pp
Other income, net	0.01
Tax	−0.17
Net profit	0.72	30% margin	+1pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q2 FY25 (period ends Jun 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	2.46	100%	+4%
Livestock	0.64	26%
Dermatology	0.46	19%
Other revenue	0.37	15%
Cattle	0.32	13%
Anti infective products	0.22	9%
Pain sedation	0.22	9%
Swine	0.12	5%
Animal health diagnostics	0.11	4%
Cost of revenue	−0.65	26%
Gross profit	1.81	74% margin	+2pp
SG&A	−0.62	25%	+0pp
Other	−0.29	12%	+0pp
Operating profit	0.91	37% margin	+3pp
Tax	−0.19
Net profit	0.72	29% margin	+3pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

Financial health

The balance sheet, the quarter's capital flow, the debt schedule and the capital structure of the quarter shown above.

Every set of results we hold, newest first. Open one on its own page.

Quarter	Period	Reported	Revenue	Year over year	Operating margin	Net profit	Net margin
Q2 FY26 Apr 1 – Jun 30, 2026 reported Aug 6, 2026 Operating margin 35% Net profit $0.69B	Apr 1 – Jun 30, 2026	Aug 6, 2026	$2.47B	+0%	35%	$0.69B	28%
Q1 FY26 Jan 1 – Mar 31, 2026 reported May 7, 2026 Operating margin 33% Net profit $0.60B	Jan 1 – Mar 31, 2026	May 7, 2026	$2.26B	+3%	33%	$0.60B	27%
Q4 FY25 Oct 1 – Dec 31, 2025 reported Feb 12, 2026 Operating margin 33% Net profit $0.63B	Oct 1 – Dec 31, 2025	Feb 12, 2026	$2.41B	+4%	33%	$0.63B	26%
Q3 FY25 Jul 1 – Sep 30, 2025 reported Nov 4, 2025 Operating margin 36% Net profit $0.72B	Jul 1 – Sep 30, 2025	Nov 4, 2025	$2.40B	+1%	36%	$0.72B	30%
Q2 FY25 Apr 1 – Jun 30, 2025 reported Aug 5, 2025 Operating margin 37% Net profit $0.72B	Apr 1 – Jun 30, 2025	Aug 5, 2025	$2.46B	+4%	37%	$0.72B	29%